«We found that pemetrexed combined with cisplatin is less toxic, well tolerated, and should be developed for further treatment of cervical cancer,»
said gynecologic oncology specialist Dr. David Miller, Professor of Obstetrics and Gynecology and a member of the Harold C. Simmons Cancer Center.
Not exact matches
«Although FDA approval is critically important for introducing a new screening test or algorithm, providers ultimately rely on guidance or guidelines to help them make the best decisions for their patients and want to understand advantages, disadvantages and unknowns associated with a new screening approach,»
said Huh, who is a senior scientist for the UAB Comprehensive Cancer Center, Director of the UAB Division of
Gynecologic Oncology, and is also a board member for both the American Society for Colposcopy and Cervical Pathology and the Society of
Gynecologic Oncology.
«Estimating from various studies that looked at increasing BMI and endometrial cancer risk, a woman with a Body Mass Index (BMI) of 40 would have approximately eight times greater risk of endometrial cancer than someone with a BMI of 25,»
said first author Kristy Ward, MD, the senior
gynecologic oncology fellow in the Department of Reproductive Medicine at UC San Diego School of Medicine.
The combination of drugs appeared less toxic than standard chemotherapy, were relatively inexpensive and should be clinically evaluated,
said Dwayne G. Stupack, PhD, the study's senior author and associate professor in the dDivision of
Gynecologic Oncology at Moores Cancer Center.
«While the presence of lymphocytes in tumors is often associated with better clinical outcomes, this research adds clarity on the diversity of T cells within the tumor environment and their influence on ovarian cancer outcomes,»
says first author Kunle Odunsi, MD, PhD, FRCOG, FACOG, Deputy Director, M. Steven Piver Professor and Chair of
Gynecologic Oncology, and Executive Director of the Center for Immunotherapy at Roswell Park.
«Given that pemetrexed combined with cisplatin may be less toxic than and as active as cisplatin plus paclitaxel and that it can be combined with bevacizumab, investigating the comparison of cisplatin - pemetrexed plus bevacizumab with cisplatin - paclitaxel plus bevacizumab would be the next appropriate step,»
said Dr. Miller, who holds the Amy and Vernon E. Faulconer Distinguished Chair in Medical Science and the Dallas Foundation Chair in
Gynecologic Oncology.
«Hysterectomy is the second most common
gynecologic surgery, and most are done for benign reasons, because most physicians believe that this surgery has minimal long - term risks,»
says Dr. Laughlin - Tommaso.
«This is the first national study to identify specific regions of the United States where residents may be at an increased risk for poor clinical outcomes — including misdiagnoses and late detection — as a result of limited access to specialized
gynecologic cancer care,» says David Shalowitz, MD, a fellow in the division of Gynecologic Oncology at the Perelman School of Medicine at the University of Pennsylvania, and lead author on
gynecologic cancer care,»
says David Shalowitz, MD, a fellow in the division of
Gynecologic Oncology at the Perelman School of Medicine at the University of Pennsylvania, and lead author on
Gynecologic Oncology at the Perelman School of Medicine at the University of Pennsylvania, and lead author on the study.
Our findings suggest that abstinence from regular physical activity is associated with increased odds of cervical cancer,»
says J. Brian Szender, MD, MPH, lead author of the study and a fellow in the Department of
Gynecologic Oncology at Roswell Park.
The drug, birinapant, sensitizes the CA125 - negative cells to the chemotherapy by restoring apoptosis, or programmed cell death,
said Dr. Sanaz Memarzadeh, a senior author of the study and a UCLA
gynecologic cancer surgeon.
«Once the ovarian cancer becomes drug resistant we can not cure it,»
says Rodriguez a
gynecologic oncologist who provides treatment to ovarian cancer patients and is director of the precision medicine initiative at Rutgers Cancer Institute of New Jersey.
«Now that we know exactly how changes in EMSY spur cancer cell growth, we can start to design therapies to specifically target that activity and hopefully stop it,»
says senior author Douglas Levine, MD, director of the Division of
Gynecologic Oncology at NYU Langone and its Perlmutter Cancer Center.
«Our algorithm allows us to be much smarter about whom we operate on up front, providing a more individualized approach to surgery that's led to better results for our patients,»
said Anil Sood, M.D., professor of
Gynecologic Oncology and Reproductive Medicine and senior author of the paper.
«The shift away from brachytherapy is concerning, and has directly lowered the survival rates of cervical cancer patients,»
said Akila Viswanathan, MD, MPH, director of BWH
Gynecologic Radiation Oncology, senior study author.
The University of Chicago's multidisciplinary team of
gynecologic oncologists, medical oncologists, radiation oncologists, and pathologists «will continue to be committed to providing patients with as many pre - and post-surgical treatment options as possible,» Yamada
said.
«We've known for years that how well a patient does is directly related to the amount of tumor that the surgeon removes and the amount that's left behind,»
says Michael Birrer, who began working with Belcher when he was head of medical
gynecologic oncology at Massachusetts General Hospital.
Previous research (the
Gynecologic Oncology Group's GOG181B trial) has suggested that trastuzumab is inactive in HER2 / neu - expressing endometrial carcinomas, and in the current study, nearly half of the participants «ultimately did not have tumoral HER2 / neu gene amplification,» Dr. Santin
said.
The results suggest that assessing baseline QoL in women with PRR - ROC might help identify which patients are unlikely to benefit from palliative chemotherapy,
said lead study author Felicia Roncolato, MBChB, FRACP, of St. George Hospital in Sydney, Australia, on behalf of the
Gynecologic Cancer Intergroup Symptom Benefit Group.
«Visualizing how cancer cells interact with a tumor microenvironment that accurately reflects the complex biology of ovarian cancer should help us understand the mechanisms underlying metastatic progression as well as identify new therapeutics that can inhibit this process,»
said clinical
gynecologic oncologist Ernst Lengyel, MD, PhD, senior author of the study and a professor of obstetrics and gynecology at the University of Chicago.
It clearly shows that those who had maintenance [Avastin] had improved profession - free survival,»
said Dr. Robert Morgan, co-director of the
gynecologic oncology program at City of Hope Cancer Center in Duarte, Calif. «I think we have to wait for longer term outcomes before we make definite conclusions.
Next Page: Guidelines not a major overhaul [pagebreak] Mark Einstein, MD, an associate professor of
gynecologic oncology at Montefiore Medical Center, in the Bronx, N.Y., and a spokesman for the Society of Gynecologic Oncology, says the new guidelines are a «data - driven fine - tuning,» not a majo
gynecologic oncology at Montefiore Medical Center, in the Bronx, N.Y., and a spokesman for the Society of
Gynecologic Oncology, says the new guidelines are a «data - driven fine - tuning,» not a majo
Gynecologic Oncology,
says the new guidelines are a «data - driven fine - tuning,» not a major overhaul.
But surgeons today are getting more aggressive, seeking to remove all evidence of cancer from the get - go,
says Barbara Goff, MD, director of
gynecologic oncology at the University of Washington.
«Ovarian cancer is often diagnosed too late,»
said Dr. David Fishman, director of the cancer center and
gynecologic oncology at NewYork - Presbyterian / Queens.
«This study confirms that long - term use [of the pill] causes a profound reduction in the risk of ovarian and endometrial cancers,»
said Dr. Stephen Rubin, chief of
gynecologic oncology at Fox Chase Cancer Center in Philadelphia.
Dr. Stephanie Blank, a professor of
gynecologic oncology at the Icahn School of Medicine at Mount Sinai in New York City,
said she generally agrees with the task force recommendations «because we do not have an effective screening test.»
«I might expect to see a 25 - pound ovarian tumor, but a 132 - pound tumor is very rare,»
said lead surgeon Vaagn Andikyan, MD, a
gynecologic oncologist at Danbury Hospital, in a statement.
Health care providers
say they can pick up on myriad
gynecologic conditions during a pelvic exam, including cancers of the cervix, vagina, vulva, ovaries and endometrium, sexually transmitted diseases, genital warts and genital herpes, uterine fibroids, ovarian cysts and more.